Tanespimycin (17-AAG)

Name: Tanespimycin (17-AAG)
Brand: Selleck Chemicals
SKU: S1141
Rating: 5 (68 reviews)

For research use only.

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

68 publications

Tanespimycin (17-AAG) Chemical Structure

CAS No. 75747-14-7

Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.

Selleck's Tanespimycin (17-AAG) has been cited by 68 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Cancers (Basel), 2020, 7;12(4)

PubMed: 32272809 ( click the link to review the publication )

Mol Cell Biol, 2020,

PubMed: 32868290 ( click the link to review the publication )

Phytomedicine, 2020,

PubMed: 32896707 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Cell, 2019, 75(4):823-834

PubMed: 31302001 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5043

PubMed: 31695040 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):737

PubMed: 31570706 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31370342 ( click the link to review the publication )

Front Cell Dev Biol, 2019, 7:204

PubMed: 31608279 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:2050183

PubMed: 31178953 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29283

PubMed: 31595984 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(2):220-233

PubMed: 31516744 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5637

PubMed: 30948782 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(2):312-324

PubMed: 30745823 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 371:63-73

PubMed: 30953615 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):102

PubMed: 30678647 ( click the link to review the publication )

Exp Eye Res, 2019, 189:107821

PubMed: 31589841 ( click the link to review the publication )

J Natl Cancer Inst, 2018, 110(4):390-399

PubMed: 29202196 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )
Cell Physiol Biochem, 2018, 47(6):2199-2215

PubMed: 29975948 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):1051-1060

PubMed: 29440291 ( click the link to review the publication )

Mol Oncol, 2018,

PubMed: 29797762 ( click the link to review the publication )

Mycoses, 2018, 61(11):853-856

PubMed: 29998564 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

EMBO J, 2017, 36(5):646-663

PubMed: 28093501 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(3):543-554

PubMed: 27592300 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28619760 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4546

PubMed: 28674407 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 329:282-292

PubMed: 28624441 ( click the link to review the publication )

Am J Transl Res, 2017, 9(11):4945-4953

PubMed: 29218092 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2219-2226

PubMed: 28458565 ( click the link to review the publication )

Cell, 2017, 170(5):845-859

PubMed: 28823557 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Nat Commun, 2016, 7:13122

PubMed: 27959342 ( click the link to review the publication )

Cancer Res, 2016, 76(4):965-73

PubMed: 26676744 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26804171 ( click the link to review the publication )

Oncogene, 2016, 35(29):3854-3865

PubMed: 26657151 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Biochem J, 2016, 473(12):1733-44

PubMed: 27059856 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Cancer Biol Ther, 2015,

PubMed: 25692408 ( click the link to review the publication )
Oncotarget, 2015, 6(17):14796-813

PubMed: 26142707 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Mol Cancer, 2014, 15:30

PubMed: 24927996 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805 ( click the link to review the publication )

Exp Gerontol, 2014, 52:55-69

PubMed: 24486130 ( click the link to review the publication )

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629 ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213 ( click the link to review the publication )

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801 ( click the link to review the publication )

Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003 ( click the link to review the publication )

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451 ( click the link to review the publication )

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234 ( click the link to review the publication )

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504 ( click the link to review the publication )

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	NFPGbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYf3TlRPUUN3ME2wMlAxODNyMzFOwG0>	M1u1dXNCVkeHUh?=
IST-MEL1	NUnRXGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwMECwOFA4KM7:TR?=	NWLjV5Y3W0GQR1XS
NCI-SNU-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LJe2lEPTB;MD6wNFIxPyEQvF2=	NVvEWplZW0GQR1XS
FADU	M17FNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;lfmdtUUN3ME2wMlAxOjB7IN88US=>	NWjWN2lGW0GQR1XS
C32	NE\1NHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXizb4pHUUN3ME2wMlAxOzB2IN88US=>	MVzTRW5ITVJ?
D-566MG	NVjsVlB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fzbGlEPTB;MD6wNFM6KM7:TR?=	NIfOdVRUSU6JRWK=
LXF-289	NWDm[ot4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXFXoRKSzVyPUCuNFA1OTlizszN	MkDQV2FPT0WU
HGC-27	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLETWM2OD1yLkCwOVEh\|ryP	M3vIVHNCVkeHUh?=
RPMI-7951	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwMEC3NVch\|ryP	NVHie\|VyW0GQR1XS
HSC-3	NIjqcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTyTWM2OD1yLkCwPVI6KM7:TR?=	MVnTRW5ITVJ?
MIA-PaCa-2	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWT5ZnpZUUN3ME2wMlAyODB7IN88US=>	MYnTRW5ITVJ?
KS-1	NV\KRYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDHRm1yUUN3ME2wMlAyOzV3IN88US=>	NVPVbJBNW0GQR1XS
CAL-51	NYLacGRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\TXJlKSzVyPUCuNFE1ODVizszN	NXfvbYZLW0GQR1XS
MDA-MB-361	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkP3TWM2OD1yLkCxOFk2KM7:TR?=	M1LiOXNCVkeHUh?=
TI-73	NXPyfG5KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYewU41FUUN3ME2wMlAyPzl4IN88US=>	M1\Q[XNCVkeHUh?=
AGS	NHjQd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwMEG5N\|gh\|ryP	M1vDeHNCVkeHUh?=
NCI-H460	NWDH[pU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMEG5O\|Qh\|ryP	NHPjVoNUSU6JRWK=
A204	MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPp[mpKSzVyPUCuNFIzPDlizszN	NHW2bFdUSU6JRWK=
CHL-1	Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnG1TWM2OD1yLkCyNlUyKM7:TR?=	MXvTRW5ITVJ?
DU-4475	NInveJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjOS2dTUUN3ME2wMlAzOjZzIN88US=>	MUXTRW5ITVJ?
CGTH-W-1	M3jGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX74fmpSUUN3ME2wMlAzOzR7IN88US=>	NVvidGd2W0GQR1XS
HCC2218	MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zQc2lEPTB;MD6wNlQ6PCEQvF2=	MVzTRW5ITVJ?
A2780	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYW1XHFlUUN3ME2wMlAzPTNzIN88US=>	Mnz3V2FPT0WU
NCI-H720	NWfFb3ppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HLU2lEPTB;MD6wNlU1PiEQvF2=	MWPTRW5ITVJ?
NCI-N87	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwMEK1PVMh\|ryP	NEnWfo5USU6JRWK=
CHP-212	NXnQdFNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfB[HBKUUN3ME2wMlAzPjJ6IN88US=>	M4fqbXNCVkeHUh?=
NCI-H23	NUe3cVN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLFTWM2OD1yLkCyOlY2KM7:TR?=	NW\hTFFrW0GQR1XS
D-263MG	M1HBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\TTmNpUUN3ME2wMlAzPzh4IN88US=>	Mlv0V2FPT0WU
ME-180	NEjsT\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFG5OXRKSzVyPUCuNFI5QTFizszN	NI\CO3JUSU6JRWK=
SW982	NX\kNo9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwMEK5PVkh\|ryP	Mn3zV2FPT0WU
OE19	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LlZmlEPTB;MD6wN\|A4PyEQvF2=	NIDBTHNUSU6JRWK=
SK-LU-1	NYrNRWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7LO5ZoUUN3ME2wMlA{ODh{IN88US=>	MnjKV2FPT0WU
H4	M3zwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\VWndtUUN3ME2wMlA{ODlizszN	NXPTUopmW0GQR1XS
HT-144	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\rUGlEPTB;MD6wN\|A6OyEQvF2=	NXfZS\|RLW0GQR1XS
SK-UT-1	NFmwPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwMEOxO\|gh\|ryP	MWrTRW5ITVJ?
D-336MG	M1L4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwMEOzNFkh\|ryP	NX7yelZnW0GQR1XS
MDA-MB-175-VII	NF3MOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMEOzOVQh\|ryP	MnHNV2FPT0WU
GAMG	M3Hn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrj[XNKSzVyPUCuNFM1OzVizszN	MVTTRW5ITVJ?
CP50-MEL-B	NFjjR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TNOmlEPTB;MD6wN\|Q2KM7:TR?=	MXLTRW5ITVJ?
OVCAR-5	Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3wTWM2OD1yLkCzOFgh\|ryP	NELpfZZUSU6JRWK=
SK-MES-1	M2nnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvhTWM2OD1yLkCzOlA3KM7:TR?=	NXPMV5pWW0GQR1XS
VM-CUB-1	MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NID5cmhKSzVyPUCuNFM3PTdizszN	MkP0V2FPT0WU
WM-115	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjBO\|Z5UUN3ME2wMlA{PzZ{IN88US=>	NF60Um9USU6JRWK=
DSH1	MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TCZWlEPTB;MD6wN\|gxPyEQvF2=	NYnWcIt6W0GQR1XS
Becker	NYDJ[mVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwMEO4PFUh\|ryP	MmfXV2FPT0WU
SW962	M33SXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMEO5OFUh\|ryP	MnXtV2FPT0WU
TYK-nu	NF\2elRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorpTWM2OD1yLkCzPVg2KM7:TR?=	MX3TRW5ITVJ?
HO-1-N-1	M{jafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfWTWM2OD1yLkC0NFIyKM7:TR?=	NUnrOVJ1W0GQR1XS
T98G	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojlTWM2OD1yLkC0NVA{KM7:TR?=	M37B[HNCVkeHUh?=
ACN	NXnTcnJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXhV3lKSzVyPUCuNFQyPjJizszN	M3zGUHNCVkeHUh?=
SW780	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfYfYM1UUN3ME2wMlA1OjB\|IN88US=>	MmPtV2FPT0WU
Detroit562	M3\qbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMESyN\|kh\|ryP	NUPEdFFMW0GQR1XS
BB49-HNC	NWrWRmpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITtZ3FKSzVyPUCuNFQzPDNizszN	MkKzV2FPT0WU
HN	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M161PGlEPTB;MD6wOFI4OiEQvF2=	M1zSXHNCVkeHUh?=
H9	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzSZ5k6UUN3ME2wMlA1OzdzIN88US=>	NWnCSGliW0GQR1XS
VA-ES-BJ	MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zOR2lEPTB;MD6wOFQ1PyEQvF2=	NHjlW2NUSU6JRWK=
MEL-JUSO	NVPpeZl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;kWWlEPTB;MD6wOFQ4PSEQvF2=	MorKV2FPT0WU
BT-474	NVzFOJZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jKeGlEPTB;MD6wOFUh\|ryP	M1nvT3NCVkeHUh?=
CaR-1	NEfaPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7uUmFwUUN3ME2wMlA1PTR7IN88US=>	M1vkd3NCVkeHUh?=
PSN1	NHPTelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMES2NFMh\|ryP	MV;TRW5ITVJ?
KYSE-510	NXXybnlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwMES2OFkh\|ryP	MWHTRW5ITVJ?
KP-4	NFm3dFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFOzXWxKSzVyPUCuNFQ4PTNizszN	NWntNZRpW0GQR1XS
KYSE-410	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;ENGlKSzVyPUCuNFQ4PzJizszN	M4m4WnNCVkeHUh?=
G-402	NXzDbGVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHoSFNKSzVyPUCuNFQ4QDlizszN	Mon4V2FPT0WU
DOK	M2jKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLwTWM2OD1yLkC0PVAzKM7:TR?=	NFnISWxUSU6JRWK=
COR-L88	MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXG0eFZNUUN3ME2wMlA1QTF{IN88US=>	NV3NOXZkW0GQR1XS
SKG-IIIa	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HwcGlEPTB;MD6wOFk5PiEQvF2=	MXXTRW5ITVJ?
AN3-CA	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwMEWg{txO	NXq1cmpOW0GQR1XS
SW48	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMEWwN\|kh\|ryP	MoTOV2FPT0WU
YKG-1	NELQVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\IVpJlUUN3ME2wMlA2ODdzIN88US=>	NI[1[HlUSU6JRWK=
KYSE-150	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXlRVlKSzVyPUCuNFUzOzVizszN	NF7pS5FUSU6JRWK=
HuO-3N1	MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMEWyN\|ch\|ryP	MX\TRW5ITVJ?
LB1047-RCC	NG\yZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfrSZFKSzVyPUCuNFUzQTZizszN	M{HMcHNCVkeHUh?=
NCI-H2030	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTWOZR4UUN3ME2wMlA2PDF2IN88US=>	NHjuUXVUSU6JRWK=
YH-13	Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPNTWM2OD1yLkC1O\|IzKM7:TR?=	MYTTRW5ITVJ?
5637	NF\2PFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELx[nhKSzVyPUCuNFU4PCEQvF2=	M2TIPXNCVkeHUh?=
LOXIMVI	M3K4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfLUVNKSzVyPUCuNFU5PzJizszN	M2jZbnNCVkeHUh?=
GT3TKB	M1LaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHxTWM2OD1yLkC1PVQzKM7:TR?=	NXHEUVFTW0GQR1XS
TCCSUP	NFPOfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4q3OmlEPTB;MD6wOVk3PCEQvF2=	M{K1cnNCVkeHUh?=
EPLC-272H	NGj1UGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwME[yNFUh\|ryP	NX;WW3lZW0GQR1XS
LU-99A	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HLZWlEPTB;MD6wOlI{PyEQvF2=	MWHTRW5ITVJ?
NCI-H1755	M17XfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3S3ZWlEPTB;MD6wOlM1OSEQvF2=	M2n6WnNCVkeHUh?=
KM12	NWnTenM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13DNmlEPTB;MD6wOlM1QCEQvF2=	M2rQWHNCVkeHUh?=
SF295	NF:xXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4O0TGlEPTB;MD6wOlQ2OiEQvF2=	NEjjNpBUSU6JRWK=
MZ2-MEL	MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwME[1OVMh\|ryP	MVnTRW5ITVJ?
HEC-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwME[1PFgh\|ryP	MX;TRW5ITVJ?
SW684	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LabmlEPTB;MD6wOlU6OSEQvF2=	M4X3bHNCVkeHUh?=
SF539	NFnaW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwME[2PFEh\|ryP	MUTTRW5ITVJ?
GMS-10	MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37pbWlEPTB;MD6wOlY6QSEQvF2=	NV71Z2lnW0GQR1XS
MV-4-11	NEXjVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwME[4NFMh\|ryP	MUPTRW5ITVJ?
HT-29	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vTWGlEPTB;MD6wOlkyQSEQvF2=	MVjTRW5ITVJ?
23132-87	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDtSItKSzVyPUCuNFY6PSEQvF2=	NYC3PY5bW0GQR1XS
SW620	MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3W3eWlEPTB;MD6wO\|AzPiEQvF2=	MYnTRW5ITVJ?
HCC1806	NEX6RWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HUXmlEPTB;MD6wO\|E{OSEQvF2=	M3HtcXNCVkeHUh?=
Hs-578-T	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13iZmlEPTB;MD6wO\|IxQCEQvF2=	M{XhOXNCVkeHUh?=
A2058	M{fKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjEcXkzUUN3ME2wMlA4OjJ6IN88US=>	NFm0VFdUSU6JRWK=
MEL-HO	NYPpcox2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPnNmFKSzVyPUCuNFczPTVizszN	M4HIPXNCVkeHUh?=
HCC2998	NYC3e5ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwMEezOFch\|ryP	M{PXSnNCVkeHUh?=
HuO9	NV20[mlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofhTWM2OD1yLkC3OVg6KM7:TR?=	NVzHVoVLW0GQR1XS
CAL-39	MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1n5U2lEPTB;MD6wO\|c3PiEQvF2=	NFLXO\|JUSU6JRWK=
M14	MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\XRmlEPTB;MD6wO\|kyOyEQvF2=	M1TSTnNCVkeHUh?=
BFTC-909	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPMSWpKSzVyPUCuNFc6PjlizszN	MUfTRW5ITVJ?
TE-11	NXfWOIJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojlTWM2OD1yLkC3PVk3KM7:TR?=	NX7QV2dxW0GQR1XS
TGBC1TKB	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXLcZRKSzVyPUCuNFgxPDNizszN	MXLTRW5ITVJ?
L-363	NX\qb5o4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;iclR3UUN3ME2wMlA5OjB4IN88US=>	NIfHeI9USU6JRWK=
A431	M2fHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDSTWM2OD1yLkC4NlEh\|ryP	MVrTRW5ITVJ?
MKN45	M{GwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPx[2hYUUN3ME2wMlA5OjF7IN88US=>	NF3sOJVUSU6JRWK=
HT-1080	M1nkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDBVWRKSzVyPUCuNFg1OzlizszN	M{TuXXNCVkeHUh?=
OVCAR-8	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXn1NZZEUUN3ME2wMlA5PjJ{IN88US=>	Mn7YV2FPT0WU
LCLC-97TM1	NH60NWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1Ttb2lEPTB;MD6wPFczQCEQvF2=	Mlr1V2FPT0WU
M059J	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwMEmwNlch\|ryP	M2[1T3NCVkeHUh?=
SK-MEL-2	M1nLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGH0N\|dKSzVyPUCuNFkxPiEQvF2=	MknGV2FPT0WU
TE-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlX3TWM2OD1yLkC5NlA1KM7:TR?=	MWTTRW5ITVJ?
KYSE-180	M4njcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMEmyOlIh\|ryP	MWrTRW5ITVJ?
D-247MG	NFfrOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMEm0OVUh\|ryP	NV;heVVbW0GQR1XS
8-MG-BA	MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPiNoZKSzVyPUCuNFk1PzJizszN	NUnCcoQyW0GQR1XS
NCI-H1792	Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTSTWM2OD1yLkC5OlE5KM7:TR?=	MV;TRW5ITVJ?
MCF7	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LNR2lEPTB;MD6wPVY4PyEQvF2=	MXLTRW5ITVJ?
NCI-H2122	NF;H[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;STWM2OD1yLkC5O\|Q2KM7:TR?=	M{fwNHNCVkeHUh?=
EFO-27	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEm5PVch\|ryP	Mof5V2FPT0WU
LB2241-RCC	M{\VcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMUCwOVQh\|ryP	M2PWOXNCVkeHUh?=
SN12C	M1nUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMUCxNFch\|ryP	MkfRV2FPT0WU
A498	NUfLWXAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMUCxPEDPxE1?	NHTNOJFUSU6JRWK=
PANC-03-27	NIHifWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvnOJBKSzVyPUCuNVAzQDZizszN	MmXoV2FPT0WU
NCI-H1581	NVjGWIxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjqTWM2OD1yLkGwNlkh\|ryP	NYfIO3NvW0GQR1XS
U-87-MG	M3H4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rBNGlEPTB;MD6xNFMxPyEQvF2=	MYrTRW5ITVJ?
G-401	MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPFTWM2OD1yLkGwN\|U{KM7:TR?=	NHL2[lhUSU6JRWK=
SiHa	NXrCUnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwMUC0PFYh\|ryP	NGTleXpUSU6JRWK=
U251	NITpeXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4izbWlEPTB;MD6xNFUzPSEQvF2=	MXPTRW5ITVJ?
MMAC-SF	MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1X5OmlEPTB;MD6xNFU{OSEQvF2=	M37BPHNCVkeHUh?=
BB65-RCC	MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnT1TWM2OD1yLkGwOVU1KM7:TR?=	MU\TRW5ITVJ?
NKM-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvZZ5JKSzVyPUCuNVA3PjZizszN	NETwclVUSU6JRWK=
HD-MY-Z	NIrjU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnhTWM2OD1yLkGwPFc{KM7:TR?=	M3f3SXNCVkeHUh?=
TGBC11TKB	M4XGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXOzVGVwUUN3ME2wMlExQTB\|IN88US=>	MmTXV2FPT0WU
COLO-679	MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMUGyNVEh\|ryP	NHLhN5RUSU6JRWK=
TE-8	MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4K3V2lEPTB;MD6xNVI3PCEQvF2=	NXTXbnFkW0GQR1XS
SK-MEL-28	M1jEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMUGzNlEh\|ryP	M2nV[HNCVkeHUh?=
SH-4	NX\NOHJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLSTWM2OD1yLkGxN\|U3KM7:TR?=	M2nK[XNCVkeHUh?=
KALS-1	NYTlcYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULkVpBXUUN3ME2wMlEyOzl\|IN88US=>	MkfwV2FPT0WU
RKO	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTscmd6UUN3ME2wMlEyPzZ2IN88US=>	MYnTRW5ITVJ?
OMC-1	M{XHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXLSFBKSzVyPUCuNVE4QTdizszN	NFHVTFBUSU6JRWK=
BT-549	NIrNNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwMUG3PVkh\|ryP	MmDvV2FPT0WU
NCI-H28	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMUG4NVch\|ryP	MX;TRW5ITVJ?
RXF393	NX;yVIhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjIW\|h6UUN3ME2wMlEyQTh{IN88US=>	NULtT5J4W0GQR1XS
COLO-829	M1P0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI[2[4pKSzVyPUCuNVIxODVizszN	NFPnZWZUSU6JRWK=
HMV-II	Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXKWlBqUUN3ME2wMlEzODJizszN	NIfTZWZUSU6JRWK=
SW1990	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMUKxOVch\|ryP	M1nLW3NCVkeHUh?=
NCI-H1437	MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml32TWM2OD1yLkGyNVU4KM7:TR?=	MWnTRW5ITVJ?
SNB75	NVvE[ol2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlH0TWM2OD1yLkGyNVY6KM7:TR?=	M3fRV3NCVkeHUh?=
EW-3	Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwMUK2OlEh\|ryP	MWTTRW5ITVJ?
SAS	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PjW2lEPTB;MD6xNlY6KM7:TR?=	NUnWZnd3W0GQR1XS
NCI-H1666	MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\PTWM2OD1yLkGyO\|c1KM7:TR?=	M1y0SnNCVkeHUh?=
A375	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTtTWM2OD1yLkGyO\|c5KM7:TR?=	MVvTRW5ITVJ?
CAMA-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\zb2tKUUN3ME2wMlEzQTJ2IN88US=>	NELoS4JUSU6JRWK=
HuP-T4	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGK0d4hKSzVyPUCuNVI6PDNizszN	MoOwV2FPT0WU
NCI-H292	NVr5[YtjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMUOxNUDPxE1?	NHr3[JFUSU6JRWK=
PC-14	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2T5V2lEPTB;MD6xN\|IyOSEQvF2=	M3\MNnNCVkeHUh?=
BPH-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXj3VYRIUUN3ME2wMlE{PDFizszN	NX7xd2xoW0GQR1XS
GAK	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mli0TWM2OD1yLkGzOVY4KM7:TR?=	M4DybXNCVkeHUh?=
VMRC-RCZ	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMUO3OlIh\|ryP	MkPhV2FPT0WU
SK-MEL-24	NV63UIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoX6TWM2OD1yLkGzPFch\|ryP	MWDTRW5ITVJ?
LB831-BLC	NVn6fmdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMUO4PFMh\|ryP	NXj5OIs6W0GQR1XS
NCI-H2452	NETNdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMUO5OVYh\|ryP	Mn\xV2FPT0WU
RT-112	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPoUIRKSzVyPUCuNVQxOzVizszN	Moi3V2FPT0WU
GP5d	NF\MbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwMUSxNFQh\|ryP	MXHTRW5ITVJ?
LC-2-ad	NUmz[JoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfUfGFKSzVyPUCuNVQyOjFizszN	M3ntT3NCVkeHUh?=
MPP-89	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fUN2lEPTB;MD6xOFEzPSEQvF2=	MkDKV2FPT0WU
NUGC-3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nyUGlEPTB;MD6xOFQ4QCEQvF2=	MkfBV2FPT0WU
GI-1	M{HIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\VWZVCUUN3ME2wMlE1PTV6IN88US=>	NXrLRZE2W0GQR1XS
HCC1419	Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMUS1O\|Yh\|ryP	NXvOW3F2W0GQR1XS
SW1573	Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfsc5I1UUN3ME2wMlE1PzV6IN88US=>	M1O2OnNCVkeHUh?=
NCI-H2347	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnqzTWM2OD1yLkG0PFM6KM7:TR?=	M4LDcnNCVkeHUh?=
Mewo	NVHwZ4dET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPIdpRuUUN3ME2wMlE1QDh7IN88US=>	Mn7tV2FPT0WU
639-V	M{f6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTi[INKSzVyPUCuNVUxOTNizszN	NX31bGJsW0GQR1XS
AsPC-1	MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TE[WlEPTB;MD6xOVIzPSEQvF2=	MUnTRW5ITVJ?
NCI-H1648	MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\hbItKSzVyPUCuNVUzOzJizszN	NI[4S\|hUSU6JRWK=
786-0	NI\QO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETaWGhKSzVyPUCuNVU{QDFizszN	NFvLR4FUSU6JRWK=
ETK-1	NY\1[W9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPEOYFKSzVyPUCuNVU6KM7:TR?=	Mo[3V2FPT0WU
BxPC-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUS1SHNPUUN3ME2wMlE2QTZ4IN88US=>	NGTo[IhUSU6JRWK=
CAL-62	M2TxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMU[xOlkh\|ryP	NUnINYh1W0GQR1XS
HCC1937	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{D3W2lEPTB;MD6xOlI4PSEQvF2=	MkfyV2FPT0WU
NCI-H1299	M1qxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXn1TnpVUUN3ME2wMlE3Ojh3IN88US=>	MnPEV2FPT0WU
SW1088	Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwMU[0NVMh\|ryP	NWnyOWtGW0GQR1XS
FTC-133	M3vuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PUU2lEPTB;MD6xOlU1KM7:TR?=	NVLnSoJTW0GQR1XS
OC-314	NVLROFB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGS2VXNKSzVyPUCuNVY3QSEQvF2=	NV65eGtZW0GQR1XS
SCC-9	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2P1PGlEPTB;MD6xOlcyPiEQvF2=	MmXMV2FPT0WU
HT-1376	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMU[5N\|Yh\|ryP	MoDSV2FPT0WU
U-2-OS	NX3LelVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMUexO\|Mh\|ryP	NFS3VG1USU6JRWK=
COLO-824	M{jN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnSU4FKSzVyPUCuNVczQTRizszN	MmSwV2FPT0WU
BB30-HNC	NVXwUZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEOydJpKSzVyPUCuNVc{OyEQvF2=	MnmyV2FPT0WU
NCI-H2087	MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDzOJZKSzVyPUCuNVc{PjhizszN	MmLqV2FPT0WU
NCI-H2170	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjZZnYyUUN3ME2wMlE4PTN4IN88US=>	M1TYOnNCVkeHUh?=
SK-OV-3	NFHjSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYL3ZZRYUUN3ME2wMlE4PTdzIN88US=>	MWPTRW5ITVJ?
MZ7-mel	NFizcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXT[Jp2UUN3ME2wMlE4PjR7IN88US=>	Ml\HV2FPT0WU
NCI-H650	NXz1TmVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfubJNqUUN3ME2wMlE4Pjh{IN88US=>	Mn22V2FPT0WU
KOSC-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojzTWM2OD1yLkG3O\|M1KM7:TR?=	NETi[lhUSU6JRWK=
SCC-4	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrKTWM2OD1yLkG3O\|c4KM7:TR?=	M4PkbnNCVkeHUh?=
MDA-MB-157	NGe3R5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrrR5NKSzVyPUCuNVgxQDJizszN	NEXoeG9USU6JRWK=
KYSE-520	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTuVmZPUUN3ME2wMlE5OiEQvF2=	MYLTRW5ITVJ?
LK-2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnLTWM2OD1yLkG4N\|A{KM7:TR?=	NGnwNFNUSU6JRWK=
KNS-81-FD	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMUizPVQh\|ryP	MVHTRW5ITVJ?
IGROV-1	MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMUi0OFMh\|ryP	M{K5T3NCVkeHUh?=
DEL	NWTVeZhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TrUGlEPTB;MD6xPFQ2KM7:TR?=	MlT2V2FPT0WU
NCI-H1395	NXv5ZYF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwMUi2PFIh\|ryP	MoXXV2FPT0WU
JEG-3	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrIPGRVUUN3ME2wMlE5PzB3IN88US=>	NX2yb5VZW0GQR1XS
BCPAP	NIfteo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTTTWM2OD1yLkG4PFczKM7:TR?=	NEGwcWxUSU6JRWK=
CAL-27	M3jPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMUmwNlIh\|ryP	M1Xkd3NCVkeHUh?=
RD	Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;hTWM2OD1yLkG5NVE{KM7:TR?=	M2jPU3NCVkeHUh?=
RVH-421	NYrzV5AyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVX0SWNiUUN3ME2wMlE6OTF4IN88US=>	MVnTRW5ITVJ?
Capan-2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLBSldKSzVyPUCuNVkzPTZizszN	MWrTRW5ITVJ?
COLO-680N	NFPkOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXixVHFoUUN3ME2wMlE6OzZ2IN88US=>	M2X3[3NCVkeHUh?=
NCI-H1650	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwMkCwOVch\|ryP	NH7EXFlUSU6JRWK=
SBC-5	NV;OSZI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3VTIdZUUN3ME2wMlIxOTF6IN88US=>	M3XzXHNCVkeHUh?=
U031	NFqxepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jYbmlEPTB;MD6yNFU1PyEQvF2=	MnHxV2FPT0WU
S-117	MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Hme2lEPTB;MD6yNFU3PCEQvF2=	NH\yVFJUSU6JRWK=
DoTc2-4510	M2jUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1n0UmlEPTB;MD6yNFc3QSEQvF2=	MVfTRW5ITVJ?
AM-38	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXJUVJKSzVyPUCuNlA5PDhizszN	Mke0V2FPT0WU
A172	MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkm0TWM2OD1yLkKxNFIzKM7:TR?=	Mkm3V2FPT0WU
HPAF-II	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7pTWM2OD1yLkKxNlY1KM7:TR?=	MnvPV2FPT0WU
769-P	M1rXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjhPZJKSzVyPUCuNlEzQCEQvF2=	MXnTRW5ITVJ?
MFE-280	Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMkGyPVgh\|ryP	MWfTRW5ITVJ?
TE-9	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnP2TWM2OD1yLkKxO\|g3KM7:TR?=	M4fTWXNCVkeHUh?=
C2BBe1	NF;4OllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnFTWM2OD1yLkKyNVkh\|ryP	MlPSV2FPT0WU
EoL-1-cell	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\YTWM2OD1yLkKyNlA{KM7:TR?=	MWTTRW5ITVJ?
G-361	NYLqSo05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnPcI1LUUN3ME2wMlIzPjh{IN88US=>	MlKyV2FPT0WU
KYSE-270	M171[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV6zOVJJUUN3ME2wMlI{ODh2IN88US=>	MXTTRW5ITVJ?
TK10	NHq3UmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HMcmlEPTB;MD6yN\|EyPyEQvF2=	M4rDTnNCVkeHUh?=
ML-2	NF34SWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMkOxNVkh\|ryP	NU\hU2R7W0GQR1XS
MHH-ES-1	Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrDcoRKSzVyPUCuNlM3QDFizszN	M2PsPHNCVkeHUh?=
BHY	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMkO2PVEh\|ryP	M{XWfHNCVkeHUh?=
LS-513	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;ON\|VKSzVyPUCuNlM6PjFizszN	NX3qb2NGW0GQR1XS
COLO-678	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nJdGlEPTB;MD6yOFA1PCEQvF2=	NHjSVndUSU6JRWK=
NCI-H747	MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVf6TGY4UUN3ME2wMlI1OTZ7IN88US=>	NFPCd4RUSU6JRWK=
K5	NGrFbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4GzeWlEPTB;MD6yOFM5KM7:TR?=	NWK1cIdQW0GQR1XS
OS-RC-2	M4jpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDoR4RKSzVyPUCuNlQ2ODlizszN	MWrTRW5ITVJ?
KINGS-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPSTWM2OD1yLkK0OVI6KM7:TR?=	NVnnfoFnW0GQR1XS
SCC-25	NW\GcnNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV74N2tnUUN3ME2wMlI1PTZ\|IN88US=>	M4jrOHNCVkeHUh?=
CAPAN-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGCyT4pKSzVyPUCuNlQ4QDNizszN	NVLMSoFzW0GQR1XS
ESS-1	M3jqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLqV5NKSzVyPUCuNlQ5ODVizszN	MWTTRW5ITVJ?
TE-6	NILkVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMkW3OUDPxE1?	NVfGS4xQW0GQR1XS
LB2518-MEL	NUHJUXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XNVmlEPTB;MD6yOVc4PyEQvF2=	MXLTRW5ITVJ?
COLO-800	NIHkPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\lTWM2OD1yLkK1PFEzKM7:TR?=	NFvCZnRUSU6JRWK=
LU-134-A	MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDQTVlZUUN3ME2wMlI3OTN4IN88US=>	MkPnV2FPT0WU
NCI-H1155	MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PDNWlEPTB;MD6yOlE3OiEQvF2=	MXzTRW5ITVJ?
MFM-223	MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfyeoZKSzVyPUCuNlY{PjNizszN	MnS5V2FPT0WU
HTC-C3	NF\pcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\wWmlEPTB;MD6yOlUxPiEQvF2=	MmrqV2FPT0WU
HCT-116	M{fQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\4d2lEPTB;MD6yOlU6QSEQvF2=	NFL2OJVUSU6JRWK=
Ca-Ski	M1TKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwMk[2O\|gh\|ryP	NYnmUFlVW0GQR1XS
SBC-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33tWmlEPTB;MD6yOlc1OiEQvF2=	MoqxV2FPT0WU
NB69	NFzYfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmntTWM2OD1yLkK3NFg4KM7:TR?=	NV\EV5pvW0GQR1XS
J82	M2X4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfOTWM2OD1yLkK3NlY2KM7:TR?=	NVXyUmZ4W0GQR1XS
U-118-MG	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfhTWtKSzVyPUCuNlc2PzlizszN	MXvTRW5ITVJ?
NCI-H1355	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMkiwO\|Qh\|ryP	NXnFO\|RwW0GQR1XS
NCI-H1048	M1;Sc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMki5OVYh\|ryP	NIfaWXdUSU6JRWK=
SW954	NIPMVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLLSYdMUUN3ME2wMlI6OjJ5IN88US=>	M3frXXNCVkeHUh?=
NMC-G1	M{DuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjRSYtKSzVyPUCuNlkzPzdizszN	MXvTRW5ITVJ?
SW1710	NX:xNWZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1ToT2lEPTB;MD6yPVQ6PCEQvF2=	MVrTRW5ITVJ?
KY821	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnmNZplUUN3ME2wMlI6QDd{IN88US=>	M1vhPHNCVkeHUh?=
HCC38	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwM{CwO\|gh\|ryP	NX\PdoZOW0GQR1XS
NCI-SNU-5	NYHDV\|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULU[Xp3UUN3ME2wMlMxPTRizszN	M2SwR3NCVkeHUh?=
ES8	M3nYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVj3[3BvUUN3ME2wMlMxPzh2IN88US=>	NIntfFNUSU6JRWK=
COLO-792	NXj1OW9OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwM{GyOVEh\|ryP	NYHQRpZJW0GQR1XS
BFTC-905	NWS2SJRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlj4TWM2OD1yLkOxOVIyKM7:TR?=	NVz3Wmt{W0GQR1XS
ChaGo-K-1	M4nM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwM{G3NVUh\|ryP	MmjjV2FPT0WU
Daoy	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknVTWM2OD1yLkOxO\|I{KM7:TR?=	NXzmXopVW0GQR1XS
SJSA-1	Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX76T4Y5UUN3ME2wMlMyQDR5IN88US=>	M{exOXNCVkeHUh?=
KNS-62	M4LTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnCRYpiUUN3ME2wMlMzODh6IN88US=>	NF;oe2ZUSU6JRWK=
CAKI-1	NFXwZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwM{KxNVEh\|ryP	MXPTRW5ITVJ?
UACC-62	M2rPbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwM{KyNlch\|ryP	MnXOV2FPT0WU
HuCCT1	MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2O0VGlEPTB;MD6zNlI5OyEQvF2=	NXrpcoplW0GQR1XS
CTB-1	M2fsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTyfJVbUUN3ME2wMlMzPzV\|IN88US=>	NVLPU3ZsW0GQR1XS
NTERA-S-cl-D1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7aeYQxUUN3ME2wMlMzQDN4IN88US=>	MWDTRW5ITVJ?
T-24	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fISmlEPTB;MD6zN\|E2QSEQvF2=	NHLwU49USU6JRWK=
KYSE-70	M2LLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTKRnc{UUN3ME2wMlM{Ojh\|IN88US=>	NYPJSG06W0GQR1XS
SW626	NUTFbXJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlj3TWM2OD1yLkOzOVMzKM7:TR?=	NF3wNVlUSU6JRWK=
LB996-RCC	NUTHUIhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2mwUWlEPTB;MD6zN\|YyQSEQvF2=	NVHGd2RnW0GQR1XS
DMS-273	MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTMTWM2OD1yLkOzPVE3KM7:TR?=	NHTLZWxUSU6JRWK=
SW1783	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nRSWlEPTB;MD6zN\|k6PyEQvF2=	M2KydHNCVkeHUh?=
KU812	MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHxUnNWUUN3ME2wMlM1ODN6IN88US=>	MYfTRW5ITVJ?
HSC-2	NI\LNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;jTWM2OD1yLkO0NFU{KM7:TR?=	MUfTRW5ITVJ?
A3-KAW	NWDObXNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwM{SxOlIh\|ryP	Mn\hV2FPT0WU
COLO-684	M33iPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPhRZFKSzVyPUCuN\|Q2ODFizszN	Mn;hV2FPT0WU
NCI-H2405	Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwM{S2N\|Eh\|ryP	NUi0e4loW0GQR1XS
NCI-H2228	NE[zUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwM{WzOVch\|ryP	MV\TRW5ITVJ?
NB13	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XvWmlEPTB;MD6zOlgzQSEQvF2=	M3zoVnNCVkeHUh?=
no-11	M3vCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwM{[5OUDPxE1?	MV\TRW5ITVJ?
DK-MG	NXPaTplwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXMO2tVUUN3ME2wMlM4OTh6IN88US=>	NU\1W21UW0GQR1XS
NBsusSR	MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnXfGZ5UUN3ME2wMlM4Ojh3IN88US=>	M1nKd3NCVkeHUh?=
KP-N-YS	NH3IZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPwbmhKSzVyPUCuN\|c1PjNizszN	Ml\CV2FPT0WU
CFPAC-1	MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfX[W12UUN3ME2wMlM4PTF6IN88US=>	NHqydWhUSU6JRWK=
KARPAS-45	M2fzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUj1boJ1UUN3ME2wMlM4QDZ{IN88US=>	NWLqflJjW0GQR1XS
NCI-H1793	NI\Keo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnPXXVKSzVyPUCuN\|g2OSEQvF2=	MknwV2FPT0WU
HCE-T	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjvcnBnUUN3ME2wMlM5PjB\|IN88US=>	NYe3THlTW0GQR1XS
NCI-H520	NXj6W\|Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LsOGlEPTB;MD6zPFcxOyEQvF2=	MYfTRW5ITVJ?
HCC2157	MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwM{i3PFEh\|ryP	NWLlPXRUW0GQR1XS
EW-18	NELS[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2raeWlEPTB;MD6zPFk1OSEQvF2=	NGfEWY1USU6JRWK=
RO82-W-1	NHz2fmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;aTWM2OD1yLkO5Olk6KM7:TR?=	NX:y[4Y2W0GQR1XS
HuP-T3	Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XYNGlEPTB;MD60NFE1OyEQvF2=	NWCxOWxOW0GQR1XS
PANC-10-05	NULiV2VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrkOmMxUUN3ME2wMlQyOTdizszN	MoDnV2FPT0WU
NCI-H1703	NGjKS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUW1XVU2UUN3ME2wMlQyPDR4IN88US=>	Mn;uV2FPT0WU
TE-10	M1jadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfzTWM2OD1yLkSxOFQ4KM7:TR?=	NETKWVBUSU6JRWK=
HOS	NVrUOI1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoKyTWM2OD1yLkSxOlgzKM7:TR?=	NXrjbW5[W0GQR1XS
LN-405	M1e0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13rTWlEPTB;MD60NVY5PyEQvF2=	NYTCW\|hDW0GQR1XS
A427	NFXZSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3:2VWlEPTB;MD60NVk5OSEQvF2=	MluyV2FPT0WU
CAL-12T	NUjDbpo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\tTWM2OD1yLkSyO\|gh\|ryP	NWLsSHhRW0GQR1XS
SW756	M1j4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLDSZpKSzVyPUCuOFQyQDNizszN	NXu0UFVVW0GQR1XS
YAPC	M3myOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwNEWwPEDPxE1?	MnPiV2FPT0WU
GOTO	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\3UFlKSzVyPUCuOFUyPiEQvF2=	M3Tpe3NCVkeHUh?=
C3A	NVrWc\|F3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXIWY5KSzVyPUCuOFU1OzdizszN	M{jxU3NCVkeHUh?=
UM-UC-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fZbmlEPTB;MD60OVQ4KM7:TR?=	M2Dl[HNCVkeHUh?=
NCI-H1573	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlizTWM2OD1yLkS1OVY6KM7:TR?=	M3T2PHNCVkeHUh?=
LS-411N	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\jZZZbUUN3ME2wMlQ3PTJ5IN88US=>	MlzWV2FPT0WU
COR-L23	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTvTWM2OD1yLkS2O\|Y1KM7:TR?=	M4LRS3NCVkeHUh?=
HCE-4	NHiz[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknVTWM2OD1yLkS3OFQ3KM7:TR?=	M1riOnNCVkeHUh?=
NCI-H2291	M3vGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwNEe4PVYh\|ryP	NGTlNplUSU6JRWK=
A101D	NHHkN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;EZoVKSzVyPUCuOFgxPTNizszN	MUDTRW5ITVJ?
HT-3	NHv2b4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwNEiyNVch\|ryP	M3z5TnNCVkeHUh?=
HOP-62	NFK2UZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEf2epZKSzVyPUCuOFk5PjVizszN	M1f2PHNCVkeHUh?=
PC-3	NWe0bmNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnOTWM2OD1yLkWxOVA4KM7:TR?=	M17senNCVkeHUh?=
CTV-1	NIW0[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjjTWM2OD1yLkWyOlY6KM7:TR?=	NHrKN2dUSU6JRWK=
PANC-08-13	NIHFdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwNUOxO\|ch\|ryP	NYfyRWs4W0GQR1XS
CAL-120	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlWyTWM2OD1yLkWzN\|k6KM7:TR?=	NHX0eJZUSU6JRWK=
UMC-11	NV3KPXd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEf5TnNKSzVyPUCuOVUzOzRizszN	MXfTRW5ITVJ?
MSTO-211H	NF\ZRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfaNGZJUUN3ME2wMlU2PzZ{IN88US=>	NInMSHZUSU6JRWK=
NCI-H2126	MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwNU[4NVUh\|ryP	Mk\5V2FPT0WU
SNU-C2B	NHfQenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwNUe5O\|ch\|ryP	Mmf6V2FPT0WU
DBTRG-05MG	Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{T2U2lEPTB;MD61PFA2OyEQvF2=	NVvLWI5uW0GQR1XS
MKN1	NGTRV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTYTWM2OD1yLkW4O\|g{KM7:TR?=	MUXTRW5ITVJ?
ES3	MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHUWJhKSzVyPUCuOVkyOjRizszN	M{TBTHNCVkeHUh?=
OVCAR-3	NGrSfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFK0OJBKSzVyPUCuOVk{PDFizszN	NWfYW3EzW0GQR1XS
ACHN	NVmwPY86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnj2TWM2OD1yLk[wOVY6KM7:TR?=	NHXoT5VUSU6JRWK=
SW872	NFzQZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfi[Zp[UUN3ME2wMlYxPzZ\|IN88US=>	NV7KWm51W0GQR1XS
CP66-MEL	NETiNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwNkC5Olkh\|ryP	MojyV2FPT0WU
NCI-H661	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmWyTWM2OD1yLk[xNVA1KM7:TR?=	NWrlenpUW0GQR1XS
UACC-893	M1vUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjnWW9KSzVyPUCuOlM3QDFizszN	NEDhVphUSU6JRWK=
JVM-3	NYXNWJVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;0TWM2OD1yLk[zPFA1KM7:TR?=	MX\TRW5ITVJ?
SF268	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\xSXdKSzVyPUCuOlQ{PDlizszN	M3HQeHNCVkeHUh?=
OCI-AML2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXjTWM2OD1yLk[1N\|k4KM7:TR?=	MYjTRW5ITVJ?
RPMI-8226	M2ew[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnN[XhKSzVyPUCuOlY{OjNizszN	NVvoTWhuW0GQR1XS
MKN28	NH;MSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LIT2lEPTB;MD62OlYzPCEQvF2=	NGDHcmFUSU6JRWK=
MDA-MB-453	M{jnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfhOJBkUUN3ME2wMlY4OThizszN	MVvTRW5ITVJ?
BV-173	M3jtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXP4PZVpUUN3ME2wMlY5Pjd7IN88US=>	NWPYWHl7W0GQR1XS
NCI-H358	M13wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDYVFdKSzVyPUCuOlg4OjZizszN	MUTTRW5ITVJ?
NCI-H1651	M3P3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zVc2lEPTB;MD63JO69VQ>?	NHfhXGxUSU6JRWK=
MDA-MB-415	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnJc2VKSzVyPUCuO\|A5OjlizszN	MUDTRW5ITVJ?
8305C	MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TIS2lEPTB;MD63NlQ6QCEQvF2=	MmTPV2FPT0WU
EFM-19	M4DWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jY[mlEPTB;MD63N\|Y4OSEQvF2=	Mlz3V2FPT0WU
RERF-LC-MS	NXfrcFNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7MUZdKSzVyPUCuO\|Q3OTNizszN	NFrrfnRUSU6JRWK=
A388	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTKTWM2OD1yLke2OFY4KM7:TR?=	M3T6UnNCVkeHUh?=
GI-ME-N	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfC[oNKUUN3ME2wMlc4OjN3IN88US=>	Mo\pV2FPT0WU
IGR-1	NWe0V\|NRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;mRmlEPTB;MD63PVA1OyEQvF2=	MorwV2FPT0WU
LNCaP-Clone-FGC	M2nrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mme3TWM2OD1yLkiwNFA1KM7:TR?=	Mo\5V2FPT0WU
SK-MEL-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoK3TWM2OD1yLkixOVA5KM7:TR?=	Mn[3V2FPT0WU
UACC-257	M1fPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHewblhKSzVyPUCuPFIzOzFizszN	NWP4PWFyW0GQR1XS
OE33	MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHSxbWJKSzVyPUCuPFUyODFizszN	MVfTRW5ITVJ?
QIMR-WIL	NIT4VnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NISwTWxKSzVyPUCuPFUyPDFizszN	NIjaem5USU6JRWK=
NCI-H2009	NWDTeIo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\ITWM2OD1yLki1N\|EyKM7:TR?=	MX;TRW5ITVJ?
NCI-H522	MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwOEe3PFMh\|ryP	NI[yZ5BUSU6JRWK=
Saos-2	MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HXdGlEPTB;MD64O\|g4OSEQvF2=	M2nFfHNCVkeHUh?=
NB17	NHTJPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\3d3NKSzVyPUCuPFgxOjVizszN	MXXTRW5ITVJ?
D-392MG	M{LEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3u5c2lEPTB;MD64PVM2PiEQvF2=	MXrTRW5ITVJ?
SHP-77	MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwOUC0PFUh\|ryP	MmjGV2FPT0WU
SK-MEL-30	M1HjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPvfIdyUUN3ME2wMlkyOTh3IN88US=>	MmTWV2FPT0WU
GCIY	NXy3dVJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\uN5NKSzVyPUCuPVE5PDNizszN	MX;TRW5ITVJ?
HCC70	NVnIc2xmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvmcHVnUUN3ME2wMlkzODV7IN88US=>	NF\jZVBUSU6JRWK=
LU-65	MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4L1V2lEPTB;MD65NlU6OSEQvF2=	M13sb3NCVkeHUh?=
NCI-H1563	MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnYTWM2OD1yLkm0PFY2KM7:TR?=	Ml2yV2FPT0WU
KURAMOCHI	M3fkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwOUWxPVIh\|ryP	NELibJdUSU6JRWK=
PA-1	NUDsVHJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVL2XHJJUUN3ME2wMlk2PDJ2IN88US=>	NIW2fYVUSU6JRWK=
NOS-1	NGfUTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwOUe0PFkh\|ryP	MXTTRW5ITVJ?
NCI-H69	NV:x[2hrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3frZWlEPTB;MD65O\|Y{PCEQvF2=	NVfIXo9kW0GQR1XS
KYSE-450	MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\sZ2lEPTB;MD65PFYzPiEQvF2=	NV;pTYVzW0GQR1XS
8505C	NIWwWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULwVJg3UUN3ME2wMlk6QTh{IN88US=>	MVjTRW5ITVJ?
TGBC24TKB	NEDFOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTFwMECwPFQh\|ryP	MomxV2FPT0WU
PFSK-1	NH32b2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvnenhKSzVyPUGuNFE1OjhizszN	M1XmNXNCVkeHUh?=
EKVX	M2\XSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFu0UXJKSzVyPUGuNFMyOjFizszN	M173S3NCVkeHUh?=
RCM-1	NXO0VY5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTFwMEW1NFch\|ryP	Mm[5V2FPT0WU
SW900	M4DITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPtTWM2OD1zLkC3PFMh\|ryP	M1vLfnNCVkeHUh?=
D-542MG	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTFwMEe4OVUh\|ryP	MVnTRW5ITVJ?
SK-PN-DW	MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\veWlEPTB;MT6xNFA2PiEQvF2=	MW\TRW5ITVJ?
NCI-H727	M1XMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDo[mVnUUN3ME2xMlExOTV2IN88US=>	M{Xn[HNCVkeHUh?=
SW837	NVL6WJcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPKcYNKSzVyPUGuNVA6PTRizszN	NYTEboJkW0GQR1XS
BT-20	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PETmlEPTB;MT6xNVIxPCEQvF2=	MmW3V2FPT0WU
RH-18	NXXq[IRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfFTWM2OD1zLkGzNVA{KM7:TR?=	NFq5[4pUSU6JRWK=
TE-12	NYW3XllET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\hdWlEPTB;MT6xN\|M{OyEQvF2=	NVvoWpQyW0GQR1XS
NB10	NYjmfG9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PTXWlEPTB;MT6xN\|M1PCEQvF2=	NUX3b\|dZW0GQR1XS
AU565	NXjvR5E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HEV2lEPTB;MT6xOVk4OyEQvF2=	MV7TRW5ITVJ?
OAW-42	NVjKfmlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vDVmlEPTB;MT6xPFMxPiEQvF2=	M1[3fnNCVkeHUh?=
DJM-1	NWfXV4V4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7XTWM2OD1zLkG5PFgyKM7:TR?=	NXrMXWlNW0GQR1XS
HH	Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DLb2lEPTB;MT6yN\|g{OSEQvF2=	M3rIbHNCVkeHUh?=
LAMA-84	NXjDN2FsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTFwMkezPVQh\|ryP	MkTTV2FPT0WU
KNS-42	NEGzeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml35TWM2OD1zLkOwNlk3KM7:TR?=	M1vNOnNCVkeHUh?=
NCI-H2052	M1\L[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjJTlFDUUN3ME2xMlMxPTB5IN88US=>	MmPZV2FPT0WU
MLMA	Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzVZ4hKSzVyPUGuN\|I1ODdizszN	NHnCSolUSU6JRWK=
NB12	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzBTWM2OD1zLkO1OlM3KM7:TR?=	NWHBTJFSW0GQR1XS
NCI-H1838	M364emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;4WGlEPTB;MT6zOlMxPiEQvF2=	MXfTRW5ITVJ?
NCI-H526	NFzCT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2f3cmlEPTB;MT6zO\|g2OyEQvF2=	NHjZTGVUSU6JRWK=
LS-123	NWD4U4ppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIG3eJpKSzVyPUGuN\|kxQTRizszN	NWS2eWxVW0GQR1XS
HDLM-2	M36zVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoK2TWM2OD1zLkO5NlcyKM7:TR?=	MV;TRW5ITVJ?
MC-IXC	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTFwNEKzO\|Eh\|ryP	MnPIV2FPT0WU
HCT-15	M3Pw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTp[ItVUUN3ME2xMlQ{ODZ6IN88US=>	NXiybmxCW0GQR1XS
NCI-H596	M1e5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3UVIZKSzVyPUGuOFUxPjFizszN	M1vzbHNCVkeHUh?=
ZR-75-30	MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vteWlEPTB;MT60O\|A5OiEQvF2=	MYfTRW5ITVJ?
A704	MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LjS2lEPTB;MT62OlU3OyEQvF2=	MXTTRW5ITVJ?
OVCAR-4	M{\sZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIiyR3pKSzVyPUGuOlk3ODdizszN	M4jUXnNCVkeHUh?=
SW1417	M3nGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTpTWM2OD1zLkeyPFQ6KM7:TR?=	NY[wU2NYW0GQR1XS
CAS-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvXbXlKSzVyPUGuO\|M6OzZizszN	NYG3SGZ6W0GQR1XS
IST-SL1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLZdGhKSzVyPUGuO\|k4PTlizszN	M4LsVXNCVkeHUh?=
A253	NYXu[\|NCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTYeHB4UUN3ME2xMlgzOjN7IN88US=>	MlT4V2FPT0WU
EW-16	NHvISY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmiwTWM2OD1zLkiyPFc2KM7:TR?=	M2LvOXNCVkeHUh?=
SK-NEP-1	NGfFdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjMWJVLUUN3ME2xMlg3QTh6IN88US=>	M33VN3NCVkeHUh?=
NCI-H226	M{\XfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXnOYkyUUN3ME2xMlg6OzV7IN88US=>	M{D3VHNCVkeHUh?=
HOP-92	NXXzfWtGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nIUGlEPTB;MT65OlA6QSEQvF2=	MXLTRW5ITVJ?
NCI-H441	Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlf1TWM2OD1{LkCyN\|M4KM7:TR?=	Mn;QV2FPT0WU
LU-139	MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTJwMEOxNVQh\|ryP	NVjYOJJCW0GQR1XS
SJRH30	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFf2WXVKSzVyPUKuNFQzPTNizszN	MofCV2FPT0WU
MG-63	M{TnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnH3TWM2OD1{LkG0NVEyKM7:TR?=	Mn3lV2FPT0WU
NH-12	NI\xNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTJwMUWwNFYh\|ryP	MUTTRW5ITVJ?
NB7	NGr3bJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MluyTWM2OD1{LkG5Olc{KM7:TR?=	MXvTRW5ITVJ?
LB771-HNC	M4rp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDQTWM2OD1{LkKwOVk2KM7:TR?=	M4Pzc3NCVkeHUh?=
HCC1569	MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTJwMkS1PFMh\|ryP	M1n0c3NCVkeHUh?=
D-283MED	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HaZmlEPTB;Mj6yOFc5OiEQvF2=	NGTj[oRUSU6JRWK=
J-RT3-T3-5	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHvTWM2OD1{LkK1N\|UyKM7:TR?=	M4XYdXNCVkeHUh?=
ATN-1	NXnxPGlGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PTRWlEPTB;Mj6zN\|A5OiEQvF2=	NWXuVHV6W0GQR1XS
HCC1954	M3vMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4i3fGlEPTB;Mj6zOFQxQCEQvF2=	M4fBPHNCVkeHUh?=
SCC-15	M1Pwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHteVRKSzVyPUKuN\|k{OTJizszN	MXTTRW5ITVJ?
COLO-668	MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHhRZFKSzVyPUKuOFMzKM7:TR?=	MYLTRW5ITVJ?
LB373-MEL-D	M4facmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIixN\|dKSzVyPUKuOVQ3PzdizszN	M1LVUnNCVkeHUh?=
no-10	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\ETWM2OD1{LkW0PVQ4KM7:TR?=	MlLGV2FPT0WU
HT-1197	M4[0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofsTWM2OD1{Lk[zNVg5KM7:TR?=	MmDyV2FPT0WU
DU-145	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWqz[XhuUUN3ME2yMlc6OTZ{IN88US=>	MULTRW5ITVJ?
SK-N-AS	NYTGXYlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nrRWlEPTB;Mj64OFY6OiEQvF2=	MmjhV2FPT0WU
MOLT-4	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\iTWM2OD1{Lki1N\|IzKM7:TR?=	MkTzV2FPT0WU
EW-22	NWfGXYpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3WTWM2OD1{LkmyPFQyKM7:TR?=	NGrhWIpUSU6JRWK=
DB	NX\JOWJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnPTWM2OD1{Lkm3O\|U6KM7:TR?=	NHvpXpdUSU6JRWK=
HL-60	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEj4W5NKSzVyPUOuNFQ{PzZizszN	NG\nd\|lUSU6JRWK=
SK-N-DZ	NH:xNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHrS\|BLUUN3ME2zMlA2ODd3IN88US=>	NF;afW9USU6JRWK=
NY	MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\oT2lEPTB;Mz6wPFU1OiEQvF2=	M{joXXNCVkeHUh?=
T47D	NE\BTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlf5TWM2OD1\|LkGwOVU5KM7:TR?=	M2O4NHNCVkeHUh?=
NCI-H2029	MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHwS3VKSzVyPUOuNlI1PzdizszN	MVjTRW5ITVJ?
KARPAS-299	NHnzPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPIO4hpUUN3ME2zMlI3ODJ5IN88US=>	Ml;rV2FPT0WU
KM-H2	M17R[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTNwM{C2PEDPxE1?	M3G3UXNCVkeHUh?=
CHP-134	M2rNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjhPGVtUUN3ME2zMlQ4OzlizszN	MoDUV2FPT0WU
22RV1	MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHKOJNKSzVyPUOuOFkyPjhizszN	NXyyW\|hRW0GQR1XS
NB5	NXrxR\|l5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILDPFBKSzVyPUOuOVA3QDlizszN	NVn4c\|JRW0GQR1XS
CW-2	M13OTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\j[WFCUUN3ME2zMlU2OzF2IN88US=>	M4TCOnNCVkeHUh?=
EFO-21	NYDj[nFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3[wcmlEPTB;Mz61Olk1KM7:TR?=	MmqzV2FPT0WU
HuH-7	NETJWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPTTWM2OD1\|LkW4OFE1KM7:TR?=	MX7TRW5ITVJ?
ALL-PO	NXHi[VRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jLTmlEPTB;Mz62NlM{PSEQvF2=	M1nnSnNCVkeHUh?=
EM-2	NVPl[3FKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nyRWlEPTB;Mz62PVAyOSEQvF2=	NVPZfGRHW0GQR1XS
KLE	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDRW4dKSzVyPUOuO\|MxOjlizszN	MULTRW5ITVJ?
NEC8	M37JO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vZWGlEPTB;Mz65NVgxQCEQvF2=	M{nIXHNCVkeHUh?=
KP-N-YN	M2nad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7HTWM2OD1\|LkmzOFc3KM7:TR?=	NEXVeGFUSU6JRWK=
SK-MEL-1	NGLDTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH:xRoJKSzVyPUSuNFM2OThizszN	NULnNVVSW0GQR1XS
CAL-54	MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTRwMEW5NUDPxE1?	MXnTRW5ITVJ?
MS-1	MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLMTWM2OD12LkG2NVU2KM7:TR?=	NXrzbJVVW0GQR1XS
NCI-H209	NVzCTFVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\QeGlEPTB;ND6yPVk6QSEQvF2=	MnrGV2FPT0WU
NOMO-1	NV3QbXRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTRwM{KxN\|Eh\|ryP	MomzV2FPT0WU
RPMI-2650	M{TpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTRwM{[zNlch\|ryP	NX[0e5N3W0GQR1XS
NCI-H810	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fUdGlEPTB;ND6zPVc{PiEQvF2=	MlHhV2FPT0WU
Ca9-22	MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jNSWlEPTB;ND60OVY6OSEQvF2=	MYjTRW5ITVJ?
ES4	M2rqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTHUJlzUUN3ME20MlQ4ODl3IN88US=>	NGjqeVZUSU6JRWK=
ES6	NIi1OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTRwNEm2OVch\|ryP	MlTPV2FPT0WU
DMS-114	NXm4TnRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPDTW5KSzVyPUSuOVQ3QTFizszN	NI\pVHNUSU6JRWK=
ONS-76	NXyxSVhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWf0XXRoUUN3ME20MlU4QTVizszN	MkDwV2FPT0WU
K-562	NIfnU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIn4bFBKSzVyPUSuO\|M5OTRizszN	MY\TRW5ITVJ?
MHH-NB-11	MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTRwN{W0OlEh\|ryP	NUXjPGxzW0GQR1XS
Calu-3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjpXWZKSzVyPUSuO\|g2PDhizszN	M2qyXHNCVkeHUh?=
HT55	MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\PTWM2OD12Lki0OVQ2KM7:TR?=	MYfTRW5ITVJ?
SK-N-FI	Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnizTWM2OD12Lki1NFA6KM7:TR?=	MmrQV2FPT0WU
ES1	NVzJT5Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlj1TWM2OD12Lki2NFU4KM7:TR?=	NV71OG9bW0GQR1XS
SF126	MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjYbVRkUUN3ME20Mlk{OTh2IN88US=>	M2LP[3NCVkeHUh?=
ES5	M2XGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTVwMUK0Nlch\|ryP	MUXTRW5ITVJ?
LoVo	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLj[3BKSzVyPUWuNVU5PzFizszN	NXjsO4FiW0GQR1XS
SNU-387	Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnmzTWM2OD13LkOyN\|M6KM7:TR?=	NUjMTFM6W0GQR1XS
C8166	MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTVwM{[zN\|kh\|ryP	M{GzZ3NCVkeHUh?=
LS-1034	NHfRT\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LzOGlEPTB;NT60NlMxPyEQvF2=	NGTrVHJUSU6JRWK=
GR-ST	M1P4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTVwNUKyNFEh\|ryP	MkjoV2FPT0WU
NCI-H1092	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TheWlEPTB;NT63Nlg1OyEQvF2=	NH;abZhUSU6JRWK=
647-V	MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jre2lEPTB;NT63OFcxPiEQvF2=	NEPv[YxUSU6JRWK=
EW-13	NVnSNJB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDwSIZOUUN3ME21Mlc3PjJ5IN88US=>	MlrQV2FPT0WU
KGN	NF3ifm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{O1UGlEPTB;Nj6wPVkzOSEQvF2=	M3zaR3NCVkeHUh?=
D-423MG	M4fBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHxeY9KSzVyPU[uOFAzQDRizszN	NYfXT5MxW0GQR1XS
ECC10	NV3xWXV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HJV2lEPTB;Nz6xNFExOSEQvF2=	MmCwV2FPT0WU
TE-5	NInDVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Hn[2lEPTB;Nz60NVI6QCEQvF2=	M1v5PXNCVkeHUh?=
P12-ICHIKAWA	M4jiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moj6TWM2OD15LkS1OVI{KM7:TR?=	M{\sdXNCVkeHUh?=
NCI-H82	NF\Xc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGW2c4RKSzVyPUeuOFU4ODFizszN	NEn6VpVUSU6JRWK=
NCI-H1993	NYe3WY9xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPZN\|NKSzVyPUeuPFMxPjNizszN	NGD3[pVUSU6JRWK=
RH-1	NFjN[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXGUJZKSzVyPUeuPFUzPDRizszN	MUjTRW5ITVJ?
SW948	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTdwOU[wOFkh\|ryP	NW[1OJdzW0GQR1XS
CAL-33	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIP5NmJKSzVyPUeuPVk6OzhizszN	NGOyO3dUSU6JRWK=
U-266	NUKxbVJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo[zTWM2OD16LkG1O\|c4KM7:TR?=	NILhb2hUSU6JRWK=
CAL-72	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFO2c5pKSzVyPUiuNlA{OiEQvF2=	MmXPV2FPT0WU
SNU-423	M{DLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mny0TWM2OD17LkO2OlY3KM7:TR?=	MnfXV2FPT0WU
KG-1	NXfmPWlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPoTWM2OD17LkW4OFU3KM7:TR?=	NETrcI1USU6JRWK=
HCC1395	NHPQT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PLb2lEPTB;OT65NlM2OiEQvF2=	MWjTRW5ITVJ?
BE-13	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\HWIZKSzVyPUGwMlg5QTJizszN	MULTRW5ITVJ?
MKN7	NVfoVIxtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTFyLkm3OlUh\|ryP	MmDxV2FPT0WU
697	MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDSS\|hRUUN3ME2xNU4yPDd{IN88US=>	Moe0V2FPT0WU
LU-135	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDC[lNKSzVyPUGxMlI{ODdizszN	M2fNWXNCVkeHUh?=
ES7	MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjUVpAzUUN3ME2xNU4{OzF\|IN88US=>	NFq2TZlUSU6JRWK=
SK-HEP-1	NHH6dXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTFzLke2OFYh\|ryP	NUewNlI1W0GQR1XS
BEN	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTFzLki1NUDPxE1?	Mn7wV2FPT0WU
NCI-H1770	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1[5cmlEPTB;MUKuNVI3KM7:TR?=	NHfHN4VUSU6JRWK=
SW13	NVj4U5NnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTF{LkG1OFEh\|ryP	M{PSOnNCVkeHUh?=
MZ1-PC	NVjYVJg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTF{LkW0OVIh\|ryP	MWPTRW5ITVJ?
Mo-T	M2Tvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1i1WWlEPTB;MUKuO\|QzOSEQvF2=	NHTl[VBUSU6JRWK=
HLE	Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTF{LkiyNVUh\|ryP	MoXNV2FPT0WU
RCC10RGB	NVq3bYN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\jTWM2OD1zMz62O\|Eh\|ryP	NVXlVpdIW0GQR1XS
COLO-320-HSR	NFjJZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfNTWM2OD1zMz63N\|gyKM7:TR?=	NXLYNVd[W0GQR1XS
BHT-101	M4fLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUO5eVd[UUN3ME2xN{45OzR3IN88US=>	NVPneHRJW0GQR1XS
OCUB-M	NH7teIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWH2ZZVoUUN3ME2xOE4yPjB{IN88US=>	MVnTRW5ITVJ?
MEG-01	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTF2LkO3NFgh\|ryP	MUPTRW5ITVJ?
RS4-11	M4frNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPRWFhKSzVyPUG0Mlc1OiEQvF2=	MmrhV2FPT0WU
MN-60	NHvkTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfoeYJ6UUN3ME2xOE44QDl2IN88US=>	MljCV2FPT0WU
NCI-H1304	NFL5bY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1L2dWlEPTB;MUWuNFQzPSEQvF2=	NVzoTXV5W0GQR1XS
Ramos-2G6-4C10	MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLpTWM2OD1zNT6wOVgyKM7:TR?=	M37hdnNCVkeHUh?=
NCI-H2342	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfCU4UyUUN3ME2xOU4zODR2IN88US=>	MUTTRW5ITVJ?
LAN-6	NF[wTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfndVJKSzVyPUG1MlQ1OTRizszN	M{jkdXNCVkeHUh?=
JVM-2	Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvpbHdKSzVyPUG1MlU4PDhizszN	NWPqb\|FMW0GQR1XS
P30-OHK	M{L2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTF4LkC2NVQh\|ryP	MXXTRW5ITVJ?
C-33-A	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnhNnNDUUN3ME2xOk43OjF2IN88US=>	NHnSWJVUSU6JRWK=
RPMI-8866	NXXZbYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPzOGlQUUN3ME2xOk45PDl4IN88US=>	M3nlUXNCVkeHUh?=
NCI-H630	NUnFUmNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XFN2lEPTB;MU[uPFU{PyEQvF2=	NH3OVHlUSU6JRWK=
KYSE-140	NVnoSFY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3CfVVsUUN3ME2xO{4zODJ6IN88US=>	Ml3uV2FPT0WU
T84	NXjWOpdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHGZmtKSzVyPUG4Mlg3QTVizszN	M2Lkb3NCVkeHUh?=
KU-19-19	M4HpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3PTWM2OD1zOD65OlA5KM7:TR?=	NIiwXXdUSU6JRWK=
BALL-1	MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPWTWM2OD1zOT6zN\|k6KM7:TR?=	M{\tcnNCVkeHUh?=
Calu-6	MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3ZZlhCUUN3ME2xPU41QTJizszN	NUHYN45bW0GQR1XS
EGI-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33jTmlEPTB;MUmuOVk5KM7:TR?=	M2jOW3NCVkeHUh?=
MFH-ino	NGHF[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrwTWM2OD1zOT63OFU1KM7:TR?=	MlrnV2FPT0WU
GB-1	NWTqZ45wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LFeWlEPTB;MkCuN\|U{PSEQvF2=	MUjTRW5ITVJ?
NCI-H1693	MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTJyLk[1NFUh\|ryP	NYHC[YtlW0GQR1XS
SW1116	NFPIeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTHTWM2OD1{MD65N\|YzKM7:TR?=	M1HTc3NCVkeHUh?=
H-EMC-SS	Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTJ{LkC0OUDPxE1?	MYHTRW5ITVJ?
D-502MG	NI[wblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTJ{LkiyOlEh\|ryP	MVHTRW5ITVJ?
IA-LM	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\wTWM2OD1{Mz6yOFk{KM7:TR?=	MorhV2FPT0WU
SW1463	M{LrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHkTWM2OD1{Mz63PUDPxE1?	NIH4Zo9USU6JRWK=
JAR	NHf1SW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nhV2lEPTB;MkSuN\|I6OyEQvF2=	M{PNfXNCVkeHUh?=
HT	M3O1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXLfpVHUUN3ME2yOE41PzV\|IN88US=>	NWm1U25oW0GQR1XS
LCLC-103H	Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fLUWlEPTB;MkSuPFQ1QSEQvF2=	NYn0OXd4W0GQR1XS
SNU-449	NYjXW29UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTJ2Lki3OFEh\|ryP	M1XLbnNCVkeHUh?=
KE-37	M2G0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoW5TWM2OD1{NT6wPVI5KM7:TR?=	M3faRXNCVkeHUh?=
NCI-H1623	NVTQXI9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33t[GlEPTB;MkeuNVMxOyEQvF2=	MUXTRW5ITVJ?
MOLT-13	NWPROolST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfqSmZKSzVyPUK3MlM2OTZizszN	M2nYfHNCVkeHUh?=
COLO-741	M4S3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTNzLkOzN\|Mh\|ryP	MlLFV2FPT0WU
NB6	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXONIVSUUN3ME2zNk4zQDd4IN88US=>	NWTSVXdOW0GQR1XS
MOLT-16	NFPq[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3zTWM2OD1\|Mz6wNFU2KM7:TR?=	NI[0Z2tUSU6JRWK=
IST-MES1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVm4cHNZUUN3ME2zOE4xPTRzIN88US=>	MYLTRW5ITVJ?
A4-Fuk	NG\6PIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzjOHkxUUN3ME2zOU4xPjZizszN	M{PFfnNCVkeHUh?=
CAL-85-1	M1iwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmS5TWM2OD1\|NT6yPFE4KM7:TR?=	MWXTRW5ITVJ?
CCRF-CEM	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTN5LkG1N\|Yh\|ryP	M16zSnNCVkeHUh?=
HAL-01	MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnH1TWM2OD1\|OD60PFg6KM7:TR?=	MXPTRW5ITVJ?
HEL	MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvyPIlFUUN3ME20N{4{PDB7IN88US=>	MkPlV2FPT0WU
EW-1	M1;ZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\aUJNiUUN3ME20N{41PzZ6IN88US=>	NEHlWGNUSU6JRWK=
MDA-MB-231	NX6yXIg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nxVmlEPTB;NEWuNVE6QSEQvF2=	MYLTRW5ITVJ?
ABC-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nCUmlEPTB;NE[uPFU{QCEQvF2=	NX3mZVJFW0GQR1XS
NCI-H446	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HVTGlEPTB;NEiuOVA2QCEQvF2=	M17QS3NCVkeHUh?=
MHH-PREB-1	NVmzc5JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfRd2dPUUN3ME20PU43ODB5IN88US=>	NYnwfZB7W0GQR1XS
DOHH-2	M12wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn[0TWM2OD12OT62OlU3KM7:TR?=	NWC4OnJyW0GQR1XS
GCT	MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHH6SZpKSzVyPUS5MlY6PzZizszN	MmrOV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; PubMed: 20090920 PLoS One Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control. EGFR / PDGFR / AKT / MAPK / c-RAS; PubMed: 18682579 Neuro Oncol 17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment. pAKT / pMAPK / pRb; PubMed: 18682579 Neuro Oncol The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment. Cleaved PARP / Survivin; PubMed: 18827603 J Thorac Oncol Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control. LATS1 / p-LATS1 / YAP / CTGF; PubMed: 25712415 J Cell Mol Med Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF. The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.	20090920 18682579 18827603 25712415
Immunofluorescence	STAT3; PubMed: 27279418 Mol Med Rep Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole. YAP / TAZ; PubMed: 25290150 PLoS One Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM). β-catenin / E-cadherin; PubMed: 25290150 PLoS One Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.	27279418 25290150
Growth inhibition assay	Cell viability; PubMed: 18682579 Neuro Oncol 17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.	18682579

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	- Collapse Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Water	Insoluble
	Ethanol	'''5 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953
Smiles	CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00103272	Terminated	Drug: tanespimycin\|Drug: bortezomib	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00098488	Terminated	Drug: tanespimycin\|Biological: rituximab	B-cell Chronic Lymphocytic Leukemia\|Prolymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00118248	Completed	Drug: tanespimycin	Recurrent Thyroid Cancer\|Stage IV Follicular Thyroid Cancer\|Stage IV Papillary Thyroid Cancer\|Thyroid Gland Medullary Carcinoma	National Cancer Institute (NCI)	December 2004	Phase 2
NCT00098423	Completed	Drug: tanespimycin\|Drug: cytarabine	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia With Excess Blasts in Transformation\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	National Cancer Institute (NCI)	November 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90. VER155008 inhibits autophagy and causes reduced levels of HSP90 client proteins.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth inhibition, autophagy and apoptosis. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin (NSC 122750) is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin attenuates virus infection-induced ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) by reducing the host's inflammatory responses.
HSP990 (NVP-HSP990)

HSP990 (NVP-HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM. NVP-HSP990 induces cell cycle arrest and apoptosis.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)